Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 10—October 2003

Research

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

Brian Clarke*, Margot Hiltz*, Heather Musgrave*, and Kevin R. Forward*Comments to Author 
Author affiliations: *Dalhousie University and the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada

Main Article

Table 1

Summary of promoter/attenuator mutations and porin changes in 18 clinical strains of Escherichia coli, arranged by pulsed-field typea

PFGE type Strain MIC (μg/mL)
Patient Location Promoter mutations Attenuator mutations Outer membrane protein profile
FOX CAZ CRO
A
QE1
16
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
G to A, right stem; C to T, upstream of stem/loop
No abnormalities
A1
QE2
8
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A2
QE3
>32
<8
<8
Inpatient Ward A
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; C deletion, right stem
No abnormalities
A2
QE4
16
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A3
QE5
16
<8
<8
ER
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; C to T, left stem
No abnormalities
A4
QE6
>32
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop
No abnormalities
A5
QE7
>32
<8
<8
HCC
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; ATG deletion in loop/right stem (+27 –29)
No abnormalities
A
QE8
16
<8
<8
FD
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; G to A, left stem
No abnormalities
A
QE9
>32
16
<8
Inpatient Ward B
T insertion (–13) to consensus spacer (17 bp)
C to T, upstream of stem/loop; G to A, right stem
No abnormalities
B
QE10
>32
<8
<8
Inpatient Ward C
C to T (–42); G to A (–18); C to T (–1)
C to A, left stem; C to T, downstream of stem/loop
No abnormalities
C
QE11
>32
<8
<8
Inpatient Ward C
G to A (–18); C to T (–1)
C to T, downstream of stem/loop
No abnormalities
D
QE12
>32
<8
<8
FD
G to A (–18); C to T (–1)
C to T, downstream stem/loop
Omp F-
E
QE13
>32
16
<8
FD
G to A in spacer (–28)
C to T, downstream stem/loop
No abnormalities
F
QE14
8
<8
<8
ER
T to A (–32), new –35 box; C to T (–11), new –10 box
None
No abnormalities
G
QE15
>32
16
<8
Inpatient Ward D
T to A (-32), new –35 box
None
Omp C-
H
QE16
>32
<8
<8
HCC
None
C to T, downstream stem/loop
No abnormalities
I
QE17
16
<8
<8
FD
None
C to T, downstream stem/loop
No abnormalities
J QE18 >32 <8 <8 Inpatient Ward E None C deletion, right stem (+31); C to T, downstream stem/loop No abnormalities

aPFGE, pulsed-field gel electrophoresis; FOX, cefoxitin; CAZ, ceftazidime; CRO, ceftriaxone, HCC, Hants Community Clinic; FD, family doctor’s office; ER, emergency room.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO